Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

A large national study in Denmark following nearly 1,900 patients over almost a decade found that a minimally invasive ...

At the Texas A&M University Large Animal Teaching Hospital (LATH), a horse had a 30-lb tumor, larger than a basketball, ...

The combination of belzutifan plus lenvatinib significantly improved outcomes for patients with clear cell renal cell ...

SAN FRANCISCO -- Adjuvant durvalumab (Imfinzi) and tremelimumab (Imjudo) improved disease-free survival (DFS) in a phase III ...

A large national study in Denmark following nearly 1,900 patients over almost a decade has found that a minimally invasive ...

Long-term morbidity varies by chemotherapy regimen, with higher odds of worse renal impairment seen with EPx4 vs BEPx3.

LITTLE ROCK, Ark.- When Renie Rule began feeling unusually tired last summer, she assumed she was simply doing too much. “I’m ...

The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, ...

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of ...

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when ...